{"groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nazacitidine: Given SC or IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Treatment (Chemotherapy)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}